Gastroparesis Risk Comparison: GLP-1 Drugs vs Bariatric Surgery vs Other Approaches
Comparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and bariatric surgery helps quantify this GI complication by treatment approach.
Quick Facts
What This Study Found
Comparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and bariatric surgery helps quantify this GI complication by treatment approach.
Key Numbers
Specific incidence rates not detailed in abstract; study used a large commercial claims database for comparison.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Comparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and b
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.
- Published In:
- BMJ open gastroenterology, 12(1) (2025)
- Authors:
- Aneke-Nash, Chino, Hung, Kay Su, Wall-Wieler, Elizabeth(2), Zheng, Feibi, Sharaiha, Reem Z
- Database ID:
- RPEP-09948
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Comparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and bariatric surgery helps quantify this GI complication by treatment approach.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09948APA
Aneke-Nash, Chino; Hung, Kay Su; Wall-Wieler, Elizabeth; Zheng, Feibi; Sharaiha, Reem Z. (2025). Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.. BMJ open gastroenterology, 12(1). https://doi.org/10.1136/bmjgast-2024-001704
MLA
Aneke-Nash, Chino, et al. "Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.." BMJ open gastroenterology, 2025. https://doi.org/10.1136/bmjgast-2024-001704
RethinkPeptides
RethinkPeptides Research Database. "Comparing the risk of gastroparesis following different moda..." RPEP-09948. Retrieved from https://rethinkpeptides.com/research/aneke-nash-2025-comparing-the-risk-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.